TY - JOUR T1 - Risk of serious adverse effects with Janus kinase inhibitors JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 35 LP - 35 DO - 10.1136/dtb.2022.000078 VL - 61 IS - 3 A2 - , Y1 - 2023/03/01 UR - http://dtb.bmj.com/content/61/3/35.abstract N2 - Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022. ER -